Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. | Int J Mol Sci | 2022 | 35328658 | PubTator, text mining | PubMed |
| Interactions between miRNAs and Double-Strand Breaks DNA Repair Genes, Pursuing a Fine-Tuning of Repair. | Int J Mol Sci | 2022 | 35328651 | PubTator, text mining | PubMed |
| Liquid Profiling for Cancer Patient Stratification in Precision Medicine-Current Status and Challenges for Successful Implementation in Standard Care. | Diagnostics (Basel) | 2022 | 35328301 | PubTator, text mining | PubMed |
| Acetylation, Phosphorylation, Ubiquitination (Oh My!): Following Post-Translational Modifications on the Ubiquitin Road. | Biomolecules | 2022 | 35327659 | PubTator, text mining | PubMed |
| Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. | Cancers (Basel) | 2022 | 35326655 | PubTator, text mining | PubMed |
| Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing. | Cancers (Basel) | 2022 | 35326583 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. | Cancers (Basel) | 2022 | 35326540 | PubTator, text mining | PubMed |
| The distinct genetic features of pancreatic cancer in Chinese population. | EBioMedicine | 2022 | 35325779 | PubTator, text mining | PubMed |
| Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. | J Gynecol Oncol | 2022 | 35320892 | PubTator, text mining | PubMed |
| Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group. | Curr Oncol Rep | 2022 | 35320498 | PubTator, text mining | PubMed |
| Do current family history-based genetic testing guidelines contribute to breast cancer health inequities? | NPJ Breast Cancer | 2022 | 35319016 | PubTator, text mining | PubMed |
| DNA repair defects in cancer and therapeutic opportunities. | Genes Dev | 2022 | 35318271 | PubTator, text mining | PubMed |
| Expression of BRCA1, BRCA2, RAD51, and other DSB repair factors is regulated by CRL4WDR70. | DNA Repair (Amst) | 2022 | 35316728 | PubTator, text mining | PubMed |
| Candidate master microRNA regulator of arsenic-induced pancreatic beta cell impairment revealed by multi-omics analysis. | Arch Toxicol | 2022 | 35314868 | PubTator, text mining | PubMed |
| Double heterozygous mutation in RAD50 and ATM genes in a Peruvian family with five cancer types: a case report. | Rev Fac Cien Med Univ Nac Cordoba | 2022 | 35312250 | PubTator, text mining | PubMed |
| Establishment and Comprehensive Analysis of Underlying microRNA-mRNA Interactive Networks in Ovarian Cancer. | J Oncol | 2022 | 35310909 | PubTator, text mining | PubMed |
| Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes. | Ther Adv Med Oncol | 2022 | 35309086 | PubTator, text mining | PubMed |
| Combination of artesunate and WNT974 induces KRAS protein degradation by upregulating E3 ligase ANACP2 and β-TrCP in the ubiquitin-proteasome pathway. | Cell Commun Signal | 2022 | 35305671 | PubTator, text mining | PubMed |
| BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. | Front Cell Dev Biol | 2022 | 35300412 | PubTator, text mining | PubMed |
| The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population. | Int J Gen Med | 2022 | 35300142 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=60